A phase III trial of docetaxel–estramustine in high-risk localised prostate cancer: A planned analysis of response, toxicity and quality of life in the GETUG 12 trial
Year: 2011
Type: article
Source: European Journal of Cancer
Authors: Karim Fizazi, Francois Lesaunier, Remy Delva, Gwenaëlle Gravis, Frederic Rolland, Frank Priou, Jean-Marc Ferrero, Nadine Houedé, Loïc Mourey, Christine Theodore, Ivan Krakowski, Jean-François Berdah, Marjorie Baciuchka, Brigitte Laguerre, Aude Fléchon, Alain Ravaud, Isabelle Cojean-Zelek, Stéphane Oudard, Jean-Luc Labourey, Jean-Léon Lagrange, Paule Chinet-Charrot, Claude Linassier, Gaël Deplanque, Philippe Beuzeboc, Jean Geneve, Jean-Louis Davin, Elodie Tournay, Stephane Culine
Institutions: Institut Gustave Roussy, Centre François Baclesse, Institut Paoli-Calmettes, Centre Hospitalier Départemental Vendée, Centre Antoine Lacassagne, Institut Bergonié, Institut Claudius Regaud, Hôpital Foch, Clinique Charcot, Hôpital Sainte-Marguerite, Clinique Clémentville, Hôpital de la Timone, Centre Eugène Marquis, Centre Léon Bérard, Hôpital Saint-André, Groupe Hospitalier Diaconesses Croix Saint-Simon, Hôpital Européen Georges-Pompidou, Hôpital Universitaire Dupuytren, Centre Hospitalier Universitaire Henri-Mondor, Hôpitaux Universitaires Henri-Mondor, Centre Henri Becquerel, Hôpital Bretonneau, Hôpital Paris Saint-Joseph, Institut Curie, Institut Sainte Catherine, Hôpital Saint-Louis
Language: English
Subfield: Urology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Sanofi, Ligue Contre le Cancer, Unicancer
OpenAlex ID: W2016006304